|
ES2918580T3
(es)
*
|
2011-10-17 |
2022-07-19 |
Io Biotech Aps |
Inmunoterapia basada en PD-L1
|
|
TWI676636B
(zh)
*
|
2013-07-12 |
2019-11-11 |
Ｖｌｐ醫療股份有限公司 |
包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
|
|
US10816554B2
(en)
*
|
2014-04-04 |
2020-10-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Ligand discovery for T cell receptors
|
|
EP3936145A1
(en)
*
|
2014-07-31 |
2022-01-12 |
The University Of Western Australia |
A method for the identification of immunotherapy-drug combinations using a network approach
|
|
PL3193917T3
(pl)
|
2014-09-17 |
2022-01-17 |
Io Biotech Aps |
Kompozycje szczepionek zawierające 2,3-dioksygenazę tryptofanową lub jej fragmenty
|
|
JP6918333B2
(ja)
*
|
2014-09-17 |
2021-08-11 |
学校法人近畿大学 |
細胞性免疫に認識されるペプチド、及びそれを利用した医薬薬剤
|
|
CA2964155A1
(en)
|
2014-10-10 |
2016-04-14 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonist with checkpoint inhibitors
|
|
CA2965528A1
(en)
*
|
2014-11-14 |
2016-05-19 |
Liquid Genomics, Inc. |
Use of circulating cell-free rna for diagnosis and/or monitoring cancer
|
|
WO2016187027A1
(en)
*
|
2015-05-15 |
2016-11-24 |
Reber Genetics Co., Ltd. |
Novel baculovirus vectors and methods of use
|
|
US10889813B2
(en)
*
|
2015-09-02 |
2021-01-12 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
|
|
IL257940B
(en)
|
2015-09-16 |
2022-08-01 |
Herlev Hospital |
Vaccines that include the CC motif. Chemokine 22 or fragments thereof
|
|
HUE064857T2
(hu)
*
|
2016-03-04 |
2024-04-28 |
Io Biotech Aps |
Kombinációs terápia a rák ellen
|
|
CA3013683C
(en)
|
2016-03-14 |
2021-07-13 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for reduction of pd-l1 expression
|
|
BR112018068461A2
(pt)
|
2016-03-15 |
2019-01-22 |
Mersana Therapeutics Inc |
conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
|
|
CN109803674A
(zh)
|
2016-06-10 |
2019-05-24 |
Io生物技术公司 |
Calr和jak2疫苗组合物
|
|
JP7267014B2
(ja)
*
|
2016-06-21 |
2023-05-01 |
アイオー バイオテック エーピーエス |
癌ワクチンにおける使用のためのｐｄｌ１ペプチド
|
|
EP3478321A4
(en)
|
2016-06-30 |
2020-04-22 |
Oncorus, Inc. |
PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
WO2018140890A1
(en)
*
|
2017-01-29 |
2018-08-02 |
Zequn Tang |
Methods of immune modulation against foreign and/or auto antigens
|
|
CN108503691B
(zh)
*
|
2017-02-25 |
2021-07-23 |
复旦大学 |
一种人pd-l1蛋白高亲和性肽及其应用
|
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體－藥物結合物之組合療法
|
|
SG11201908528UA
(en)
*
|
2017-03-17 |
2019-10-30 |
Vaximm Ag |
Novel pd-l1 targeting dna vaccine for cancer immunotherapy
|
|
EP3713645A1
(en)
*
|
2017-11-24 |
2020-09-30 |
IO Biotech APS |
Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)
|
|
US11638760B2
(en)
|
2017-11-27 |
2023-05-02 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
CN111757757A
(zh)
|
2017-12-21 |
2020-10-09 |
梅尔莎纳医疗公司 |
吡咯并苯并二氮呯抗体共轭物
|
|
WO2019133847A1
(en)
|
2017-12-29 |
2019-07-04 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|
|
FR3086534B1
(fr)
*
|
2018-10-01 |
2020-11-06 |
Univ Bordeaux |
Methode pour traiter une infection par le virus de l'immunodeficience humaine
|
|
CA3117050A1
(en)
|
2018-10-29 |
2020-05-07 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
CN109593135B
(zh)
*
|
2018-12-29 |
2021-01-15 |
百奥赛图江苏基因生物技术有限公司 |
抗人pd-l1单克隆抗体及其应用
|
|
WO2020181402A1
(zh)
*
|
2019-03-10 |
2020-09-17 |
胡西木 |
一种抗肿瘤多肽及其应用
|
|
CN113249447A
(zh)
*
|
2019-04-26 |
2021-08-13 |
嘉兴允英医学检验有限公司 |
一种pd-l1表达水平检测的方法和试剂盒
|
|
BR112022005044A2
(pt)
|
2019-09-17 |
2022-07-05 |
Ohio State Innovation Foundation |
Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
|
|
WO2021208106A1
(zh)
*
|
2020-04-18 |
2021-10-21 |
北京泽勤生物医药有限公司 |
一种治疗自身免疫病的融合肽
|
|
CU24705B1
(es)
*
|
2020-10-22 |
2024-06-11 |
Ct Ingenieria Genetica Biotecnologia |
Antígeno quimérico que comprende el dominio extracelular de pd-l1
|
|
GB202103673D0
(en)
|
2021-03-17 |
2021-04-28 |
Io Biotech Aps |
Combination therapy for cancer
|
|
CN117642432A
(zh)
*
|
2021-05-17 |
2024-03-01 |
威斯康星校友研究基金会 |
用于诱导免疫耐受的合成蛋白
|
|
KR102421307B1
(ko)
*
|
2021-11-19 |
2022-07-14 |
을지대학교 산학협력단 |
암 발생 및 성장 억제를 위한 신규 항암 백신 조성물 및 그를 이용한 백신화 방법
|
|
US20250327041A1
(en)
|
2022-02-24 |
2025-10-23 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
CN114702569B
(zh)
*
|
2022-05-25 |
2023-01-10 |
深圳吉诺因生物科技有限公司 |
Pd-l1相关疫苗及其应用
|
|
WO2025043075A1
(en)
*
|
2023-08-24 |
2025-02-27 |
The Johns Hopkins University |
Methods of treating myocardial infarction, ischemia, and ischemia reperfusion injury
|
|
EP4527849A1
(en)
|
2023-09-19 |
2025-03-26 |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
Hla-independent antigen binders, such as t-cell receptors, against pd-l1
|
|
WO2026008026A1
(en)
*
|
2024-07-03 |
2026-01-08 |
Everest Medicines (China) Co., Ltd. |
Pd-l1 cancer vaccines and uses thereof
|